NervGen Pharma Corp. Common stock (NGEN)

FairStock Score: 14/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at NervGen first through Graham's lens: what is here that I can value? The company has a market capitalization of $319.7 million at the 2026-10-13 close of $1.63, but it is a 9-employee biotech with no dividend and no revenue-growth figure provided. FairStock's calculations from that close show a negative P/E of -2.91 and a P/B of 13.58, while ROE is -757.48% and ROCE is -37.70%. Those are not the marks of a mature compounding business; they describe a speculative pipeline story. Cash is being consumed: trailing free cash flow is -$25.6 million, a -8.0% FCF yield. The balance sheet shows D/E of 0.00, which is a small comfort, but Piotroski 0/9 and Altman Z 0.10 flag deep weakness, and the Lynch category is none because there are only 0 years of filed results, versus the 3 needed. The investment case rests almost entirely on NVG-291 in Phase 1b/2a for spinal cord injury, stroke, multiple sclerosis, and Alzheimer's, plus preclinical NVG-300. That is a lottery-like set of milestones. Buffett would ask for a durable moat and predictable earnings; here I see neither. Graham would demand a margin of safety; at 13.58 times book and with a FairStock score of 14/100, the price already assumes clinical success. Growth trajectory is binary: trial data can create value, but failure or dilution can destroy it. I would monitor cash burn and trial outcomes, not quarterly earnings, because the company is pre-commercial.

In plain English: NervGen Pharma is a very small biotech company developing treatments to help the nervous system repair itself, mainly for spinal cord injuries, stroke, multiple sclerosis, and Alzheimer's. The business looks weak financially: it is not profitable, spends more cash than it brings in, and has very little financial track record. At $1.63 on 2026-10-13, the price looks very expensive compared with the company's current financial numbers and depends heavily on future trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer